The Effect of DNA Concentration on the HRM performance in detecting Jak2 p.V617F variant in patients with myeloproliferative neoplasms

Alireza Moradabadi, Atefeh Soltani, A. Shariati, M. Didehdar, A. Anoushirvani, Seidamir Pasha Tabaeian
{"title":"The Effect of DNA Concentration on the HRM performance in detecting Jak2 p.V617F variant in patients with myeloproliferative neoplasms","authors":"Alireza Moradabadi, Atefeh Soltani, A. Shariati, M. Didehdar, A. Anoushirvani, Seidamir Pasha Tabaeian","doi":"10.2174/1574362418666230609112551","DOIUrl":null,"url":null,"abstract":"\n\nJanus kinase 2 (JAK2) is an intracellular signaling protein. JAK2 p. V617F is a common variant in normal karyotype myeloproliferative neoplasms (MPN). High-resolution melting (HRM) analysis is one of the essential methods for detecting the JAK2 p.V617F variant. In this study, we have investigated the effect of DNA concentration on detecting the JAK2 p.V617F variant using the HRM method.\n\n\n\nGenomic DNA was extracted from human blood and diluted ten times in distilled water from 1 to 0.03; afterward, HRM was conducted for each dilution (triplicate). Using SPSS v.20.0 software, the mean Tm of each dilution was calculated and compared.\n\n\n\nThe HRM results revealed the JAK2 wild type and variant to have Tms of 81/64°C and 80/76°C, respectively. At the endpoint of the pre-amplification, the dilutions had different emissions. The statistical analysis revealed no statistically significant differences in Tm between samples with varying DNA concentrations (P value > 0.05).\n\n\n\nThere have been no significant differences obtained in the analysis of JAK2 p.V617F point variant in different DNA dilutions, implying that the HRM analysis has no relation to DNA concentration.\n","PeriodicalId":10868,"journal":{"name":"Current Signal Transduction Therapy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Signal Transduction Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574362418666230609112551","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Janus kinase 2 (JAK2) is an intracellular signaling protein. JAK2 p. V617F is a common variant in normal karyotype myeloproliferative neoplasms (MPN). High-resolution melting (HRM) analysis is one of the essential methods for detecting the JAK2 p.V617F variant. In this study, we have investigated the effect of DNA concentration on detecting the JAK2 p.V617F variant using the HRM method. Genomic DNA was extracted from human blood and diluted ten times in distilled water from 1 to 0.03; afterward, HRM was conducted for each dilution (triplicate). Using SPSS v.20.0 software, the mean Tm of each dilution was calculated and compared. The HRM results revealed the JAK2 wild type and variant to have Tms of 81/64°C and 80/76°C, respectively. At the endpoint of the pre-amplification, the dilutions had different emissions. The statistical analysis revealed no statistically significant differences in Tm between samples with varying DNA concentrations (P value > 0.05). There have been no significant differences obtained in the analysis of JAK2 p.V617F point variant in different DNA dilutions, implying that the HRM analysis has no relation to DNA concentration.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
DNA浓度对骨髓增生性肿瘤患者检测Jak2p.V617F变体的HRM性能的影响
Janus激酶2(JAK2)是一种细胞内信号蛋白。JAK2 p.V617F是正常核型骨髓增生性肿瘤(MPN)的常见变体。高分辨率熔解(HRM)分析是检测JAK2 p.V617F变体的重要方法之一。在本研究中,我们使用HRM方法研究了DNA浓度对检测JAK2 p.V617F变体的影响。从人类血液中提取基因组DNA,并在蒸馏水中稀释10倍,从1至0.03;之后,对每个稀释液进行HRM(一式三份)。使用SPSS v.20.0软件,计算并比较每次稀释的平均Tm。HRM结果显示,JAK2野生型和变体的Tms分别为81/64°C和80/76°C。在预扩增的终点,稀释液具有不同的排放。统计分析显示,不同DNA浓度的样品之间的Tm没有统计学上的显著差异(P值>0.05)。在不同DNA稀释液中,JAK2 P.V617F点变体的分析没有获得显著差异,这意味着HRM分析与DNA浓度无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
18
审稿时长
>12 weeks
期刊介绍: In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front line of modern drug research, and a multidisciplinary approach is being used to identify and treat signaling disorders. The journal publishes timely in-depth reviews, research article and drug clinical trial studies in the field of signal transduction therapy. Thematic issues are also published to cover selected areas of signal transduction therapy. Coverage of the field includes genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases. Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.
期刊最新文献
Functional Roles of Long Non-coding RNAs on Stem Cell-related Pathways in Glioblastoma Antidiabetic Advancements In Silico: Pioneering Novel Heterocyclic Derivatives through Computational Design Exploring Squalene's Impact on Epidermal Thickening and Collagen Production: Molecular Docking Insights Atopic Dermatitis and Abrocitinib: Unraveling the Therapeutic Potential Atrial Natriuretic Peptide as a Biomarker and Therapeutic Target in Cancer: A Focus on Colorectal Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1